The FDA approved avutometinib and defactinib as a co-packaged oral combination for adults with KRAS-mutated recurrent LGSOC after prior systemic therapy. The approval is positioned as a rare “novel–novel” pairing that combines a RAF/MEK inhibitor with a focal adhesion kinase (FAK) inhibitor. The decision was supported by phase 2 RAMP-201 data, where the regimen achieved a confirmed overall response rate of 44% in the study population. Importantly for the ovarian cancer landscape, the approval is described as the first FDA authorization specifically for LGSOC, a molecularly distinct subtype from high-grade serous ovarian cancer. Clinically, the label targets a post-treatment setting and narrows eligibility to KRAS-mutated recurrent disease, creating a new combination option for a rare indication where treatment choices have historically been limited.